Oncology Liquid Biopsy for Defining Risk and Tailoring Treatment in HR+/HER2- Metastatic Breast Cancer conference reporter By Angela M. DeMichele, MD, MSCE, FASCO
Oncology Recognizing and Managing Treatment-Related Toxicities in Metastatic Breast Cancer conference reporter By Angela M. DeMichele, MD, MSCE, FASCO
Oncology Treatment Resistance in HR+/HER2- Metastatic Breast Cancer conference reporter By Sonya Reid, MD, MPH
Oncology The Treatment of HR+/HER2- Stage III Breast Cancer conference reporter By Seth A. Wander, MD, PhD